Education
About Us
Working with TipRanks
Follow Us
Insight Molecular Diagnostics (IMDX)
NASDAQ:IMDX
IMDX Stock Chart & Stats
$5.22
--
Market closed
$5.22
--
Day’s Range― - ―
52-Week Range$1.92 - $8.51
Previous CloseN/A
VolumeN/A
Average Volume (3M)42.75K
Market Cap
$149.49M
Enterprise Value$75.80M
Total Cash (Recent Filing)$18.69M
Total Debt (Recent Filing)$3.13M
Price to Earnings (P/E)―
Beta0.13
Next Earnings
Apr 01, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding28,664,436
10 Day Avg. Volume47,668
30 Day Avg. Volume42,754
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-2.53
Price to Sales (P/S)16.54
P/FCF Ratio-1.47
Enterprise Value/Market Cap0.51
Enterprise Value/Revenue17.22
Enterprise Value/Gross Profit31.46
Enterprise Value/Ebitda-1.30
Forecast
1Y Price Target
$8.50Price Target Upside62.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory ApprovalIMDX reaffirmed its goal to submit its GraftAssureDx kidney test to the FDA by the end of 2025, and expects to obtain FDA approval around mid-2026.
Revenue OpportunitiesIMDX also announced a large 5,000 patient registry utilizing GraftAssureCore (laboratory developed test), which could provide additional revenue.
Strategic PartnershipsIMDX remains confident in its partnership with BioRad, whereby BioRad and IMDX will comarket GraftAssure inside the US/Germany, and BioRad will take the commercial lead in the rest of the world.
Bears Say
Cash Flow ManagementIMDX continues to make progress in managing its cash burn though it may exceed its ~$6M per quarter target.
Earnings PerformanceEPS of -$0.34 missed Street's -$0.21.
Financial PerformanceQ3 GMs came in at 53%, down from 67% in Q2.
Insight Molecular Diagnostics News
IMDX FAQ
What was Insight Molecular Diagnostics’s price range in the past 12 months?
Insight Molecular Diagnostics lowest stock price was $1.92 and its highest was $8.51 in the past 12 months.
What is Insight Molecular Diagnostics’s market cap?
Insight Molecular Diagnostics’s market cap is $149.49M.
When is Insight Molecular Diagnostics’s upcoming earnings report date?
Insight Molecular Diagnostics’s upcoming earnings report date is Apr 01, 2026 which is in 106 days.
How were Insight Molecular Diagnostics’s earnings last quarter?
Insight Molecular Diagnostics released its earnings results on Nov 10, 2025. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.21 by $0.01.
Is Insight Molecular Diagnostics overvalued?
According to Wall Street analysts Insight Molecular Diagnostics’s price is currently Undervalued.
Does Insight Molecular Diagnostics pay dividends?
Insight Molecular Diagnostics does not currently pay dividends.
What is Insight Molecular Diagnostics’s EPS estimate?
Insight Molecular Diagnostics’s EPS estimate is -0.24.
How many shares outstanding does Insight Molecular Diagnostics have?
Insight Molecular Diagnostics has 28,664,436 shares outstanding.
What happened to Insight Molecular Diagnostics’s price movement after its last earnings report?
Insight Molecular Diagnostics reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.21. Following the earnings report the stock price went up 10.588%.
Which hedge fund is a major shareholder of Insight Molecular Diagnostics?
Currently, no hedge funds are holding shares in IMDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insight Molecular Diagnostics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.50 (62.84% Upside)
$8.50 (62.84% Upside)
Hedge Fund Trend
Decreased
By 44.4K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.71%
12-Months-Change
Fundamentals
Return on Equity
-9999.00%
Trailing 12-Months
Asset Growth
-32.39%
Trailing 12-Months
Company Description
Insight Molecular Diagnostics
Insight Molecular Diagnostics (IMDX) is a biotechnology company specializing in the development and commercialization of advanced molecular diagnostic tests. Focused on the healthcare sector, IMDX leverages cutting-edge technologies to provide innovative solutions for precision medicine, particularly in oncology and infectious diseases. The company's core products include proprietary testing platforms that offer rapid and accurate genomic analysis, enabling healthcare professionals to make informed decisions based on patients' molecular profiles.
IMDX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a generally positive outlook with significant advancements in product development and financial stability. However, the uncertainty due to the government shutdown and slower-than-expected clinical trial enrollment presents challenges.View all IMDX earnings summariesIMDX Stock 12 Month Forecast
Average Price Target
$8.50
▲(62.84% Upside)